Electra Therapeutics Prices Nasdaq IPO at $14 to $16 per Share
Electra Therapeutics has finalized terms for its initial public offering, targeting up to $347 million in gross proceeds to fund the late-stage development of its lead antibody candidate for a rare immune disorder.
Electra Therapeutics has set the pricing range for its initial public offering on the Nasdaq Global Select Market at $14 to $16 per share. The company plans to sell 21.7 million shares, a move that positions it to raise between $304 million and $347 million in gross proceeds. According to reporting by GN stocks, the capital will primarily support the ongoing SURPASS registration trial for ipsoprubart, a monoclonal antibody designed to treat secondary haemophagocytic lymphohistiocytosis.
At the midpoint of the price range, net proceeds are estimated at approximately $296 million. This figure could increase to roughly $341 million if underwriters exercise their option to purchase an additional 3.25 million shares within 30 days of pricing. The offering is led by a syndicate including Jefferies, TD Cowen, Evercore ISI, and Cantor, signaling significant institutional interest in the pre-revenue biotechnology sector.
Valuation Reflects Clinical Stage Progress
With the potential over-allotment, Electra would have approximately 60.4 million shares outstanding. At the $15 midpoint, this results in a market capitalization of around $903 million, rising to nearly $976 million at the top of the range. This valuation places the company among the larger clinical-stage listings in recent quarters, a period where many pre-revenue issuers have faced difficulty accessing public capital markets. The company will trade under the ticker symbol ETRA, with final pricing expected within days.
Ipsoprubart Targets Fatal Immune Disorder
Ipsoprubart is engineered to bind specific regulatory proteins on immune cells that drive hyperinflammation in the target syndrome. By targeting SIRPα, SIRPβ1, and SIRPγ on myeloid cells and T lymphocytes, the antibody depletes activated cells while sparing resting ones. This mechanism is critical because the disease, secondary haemophagocytic lymphohistiocytosis, lacks broadly approved therapies and carries a mortality rate approaching 50% within two months of diagnosis in its largest subtype.
Early data from the open-label SURPASS study indicates strong efficacy, with 100% overall survival at eight weeks and a 100% overall response rate by week four among the first 12 treated patients. These results compare favorably to historical controls, which show response rates of only 40% and inpatient mortality between 20% and 30%. The trial is currently enrolling adult and pediatric patients across the United States and Europe, supported by Breakthrough Therapy Designation and Priority Medicines designation, respectively.
Investors Focus On Risk Adjustment
Market participants view the offering as a test of capital discipline rather than a simple bet on scientific success. David Nilson, Director of Private Clients at Kinzey Capital Management, noted that portfolio construction relies on position limits and milestone-based tranching when a single data readout determines outcome. He emphasized that valuation in pre-revenue developers rests on pipeline potential, requiring a risk-adjusted net present value approach that discounts future revenues by the probability of market approval.
